Catheter-based intramyocardial injection of FGF1 or NRG1-loaded MPs improves cardiac function in a preclinical model of ischemia-reperfusion

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Garbayo, Elisa ^a,b   Gavira, Juan José ^b,c   De Yebenes, Manuel Garcia ^b,c   Pelacho, Beatriz ^b,c   Abizanda, Gloria ^b,c   Lana, Hugo ^a,b   Blanco Prieto, María José ^a,b   Prosper, Felipe ^b,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; LACTIC ACID; NEU DIFFERENTIATION FACTOR; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL; CELL LINE; CUTANEOUS DRUG ADMINISTRATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; HEART FUNCTION TEST; INJECTION; MALE; MINIPIG; MOUSE; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOPHYSIOLOGY; PIG; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTOR 1; HEART FUNCTION TESTS; INJECTIONS; LACTIC ACID; MALE; MICE; MYOCARDIAL REPERFUSION INJURY; NEUREGULIN-1; POLYGLYCOLIC ACID; SWINE; SWINE, MINIATURE; TREATMENT OUTCOME;

EID: 84969164688     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25932     Document Type: Article

References (60)

1. Mozaffarian D., et al. Heart Disease and Stroke Statistics-2015 Update: A Report From the American Heart Association. Circulation 131, e29-322 (2014
2. Beohar N., Rapp J., Pandya S., & Losordo D. W. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J. Am. Coll. Cardiol. 56, 1287-97 (2010
3. Awada H. K., Hwang M. P., & Wang Y. Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver. Biomaterials 82, 94-112 (2015
4. Liu X., et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J. Am. Coll. Cardiol. 48, 1438-47 (2006
5. Palmen M., et al. Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion: a fibroblast growth factor receptor, protein kinase C, and tyrosine kinase-dependent mechanism. J. Am. Coll. Cardiol. 44, 1113-23 (2004
6. Yutzey K. E. Regenerative biology: Neuregulin 1 makes heart muscle. Nature 520, 445-446 (2015
7. Udelson J. E., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 102, 1605-10 (2000
8. Bergmann M. W., et al. A pilot study of chronic, low-dose epoetin-{beta} following percutaneous coronary intervention suggests safety, feasibility, and efficacy in patients with symptomatic ischaemic heart failure. Eur. J. Heart Fail. 13, 560-8 (2011
9. Jabbour A., et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur. J. Heart Fail. 13, 83-92 (2011
10. Simons M., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105, 788-93 (2002
11. Henry T. D., et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 107, 1359-65 (2003
12. Ripa R. S., et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarc. Circulation 113, 1983-92 (2006
13. Zohlnhofer D., Kastrati A., & Schomig A. Stem cell mobilization by granulocyte-colony-stimulating factor in acute myocardial infarction: lessons from the REVIVAL-2 trial. Nat. Clin. Pract. Cardiovasc. Med. 4 Suppl 1, S106-9 (2007
14. Voors A. A., et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur. Heart J. 31, 2593-600 (2010
15. Rane A. A., & Christman K. L. Biomaterials for the treatment of myocardial infarction: a 5-year update. J. Am. Coll. Cardiol. 58, 2615-29 (2011
16. Lam M. T., & Wu J. C. Biomaterial applications in cardiovascular tissue repair and regeneration. Expert Rev. Cardiovasc. Ther. 10, 1039-49 (2012
17. Pascual-Gil S., Garbayo E., Diaz-Herraez P., Prosper F., & Blanco-Prieto M. J. Heart regeneration after miocardial infarction using synthetic biomaterials. J. Control. Release 220, 388-396 (2015
18. Jain R. A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475-2490 (2000
19. Abizaid A., & Costa J. R. New drug-eluting stents: an overview on biodegradable and polymer-free next-generation stent systems. Circ. Cardiovasc. Interv. 3, 384-93 (2010
20. Onuma Y., Ormiston J., & Serruys P. W. Bioresorbable scaffold technologies. Circ. J. 75, 509-20 (2011
21. Goodfriend A. C., et al. Novel bioresorbable stent coating for drug release in congenital heart disease applications. J. Biomed. Mater. Res. A 103, 1761-70 (2015
22. Chang M.-Y., et al. Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J. Control. Release 170, 287-94 (2013
23. Nagaoka K., et al. A New Therapeutic Modality for Acute Myocardial Infarction: Nanoparticle-Mediated Delivery of Pitavastatin Induces Cardioprotection from Ischemia-Reperfusion Injury via Activation of PI3K/Akt Pathway and Anti-Inflammation in a Rat Model. PLoS One 10, e0132451 (2015
24. Formiga F. R., et al. Sustained release of VEGF through PLGA microparticles improves vasculogenesis and tissue remodeling in an acute myocardial ischemia-reperfusion model. J. Control. Release 147, 30-37 (2010
25. Simon-Yarza T., et al. Functional benefits of PLGA particulates carrying VEGF and CoQ10 in an animal of myocardial ischemia. Int. J. Pharm. 454, 784-90 (2013
26. Formiga F. R., et al. Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration. J. Control. Release 173, 132-9 (2014
27. Emmert M. Y., et al. Transcatheter based electromechanical mapping guided intramyocardial transplantation and in vivo tracking of human stem cell based three dimensional microtissues in the porcine heart. Biomaterials 34, 2428-41 (2013
28. Smits P. C., et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J. Am. Coll. Cardiol. 42, 2063-9 (2003
29. Wolf T., et al. Detailed endocardial mapping accurately predicts the transmural extent of myocardial infarction. J. Am. Coll. Cardiol. 37, 1590-7 (2001
30. Pavo N., et al. Comparison of NOGA endocardial mapping and cardiac magnetic resonance imaging for determining infarct size and infarct transmurality for intramyocardial injection therapy using experimental data. PLoS One 9, e113245 (2014
31. Segers V. F. M., & Lee R. T. Biomaterials to enhance stem cell function in the heart. Circ. Res. 109, 910-22 (2011
32. Eckhouse S. R., et al. Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci. Transl. Med. 6, 223ra21 (2014
33. Vu T. D., et al. An autologous platelet-rich plasma hydrogel compound restores left ventricular structure, function and ameliorates adverse remodeling in a minimally invasive large animal myocardial restoration model: a translational approach: Vu and Pal Myocardial Repair: PRP, Hydrogel and Supplements. Biomaterials 45, 27-35 (2015
34. Lin Y.-D., et al. Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repair. Sci. Transl. Med. 4, 146ra109 (2012
35. Hastings C. L., et al. Drug and Cell Delivery for Cardiac Regeneration. Adv. Drug Deliv. Rev. 84, 85-106 (2015
36. Gyongyosi M., & Dib N. Diagnostic and prognostic value of 3D NOGA mapping in ischemic heart disease. Nat. Rev. Cardiol. 8, 393-404 (2011
37. Callans D. J., Ren J. F., Michele J., Marchlinski F. E., & Dillon S. M. Electroanatomic left ventricular mapping in the porcine model of healed anterior myocardial infarction. Correlation with intracardiac echocardiography and pathological analysis. Circulation 100, 1744-50 (1999
38. Odiete O., Hill M. F., & Sawyer D. B. Neuregulin in cardiovascular development and disease. Circ. Res. 111, 1376-85 (2012
39. Engel F. B., Hsieh P. C. H., Lee R. T., & Keating M. T. FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc. Natl. Acad. Sci. USA 103, 15546-51 (2006
40. Formiga F. R., et al. Biodegradation and heart retention of polymeric microparticles in a rat model of myocardial ischemia. Eur. J. Pharm. Biopharm. 85, 665-72 (2013
41. Pascual-Gil S., Simon-Yarza T., Garbayo E., Prosper F., & Blanco-Prieto M. J. Tracking the in vivo release of bioactive NRG from PLGA and PEG-PLGA microparticles in infarcted hearts. J. Control. Release 220, 388-396 (2015
42. Garbern J. C., Minami E., Stayton P. S., & Murry C. E. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 32, 2407-16 (2011
43. Guo H., et al. Sustained delivery of VEGF from designer self-assembling peptides improves cardiac function after myocardial infarction. Biochem. Biophys. Res. Commun. 424, 105-11 (2012
44. Arana M., et al. Epicardial delivery of collagen patches with adipose-derived stem cells in rat and minipig models of chronic myocardial infarction. Biomaterials 35, 143-51 (2014
45. Davis M. E., et al. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 111, 442-50 (2005
46. Zhang H., van Olden C., Sweeney D., & Martin-Rendon E. Blood vessel repair and regeneration in the ischaemic heart. Open Hear. 1, e000016 (2014
47. Galindo C. L., et al. Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failure. J. Am. Heart Assoc. 3, e000773 (2014
48. Rupert C. E., & Coulombe K. L. The roles of neuregulin-1 in cardiac development, homeostasis, and disease. Biomark. Insights 10, 1-9 (2015
49. Itoh N., & Ohta H. Pathophysiological roles of FGF signaling in the heart. Front. Physiol. 4, 247 (2013
50. Menasche P. Stem cell therapy for heart failure: are arrhythmias a real safety concern?. Circulation 119, 2735-40 (2009
51. Singelyn J. M., et al. Catheter-deliverable hydrogel derived from decellularized ventricular extracellular matrix increases endogenous cardiomyocytes and preserves cardiac function post-myocardial infarction. J. Am. Coll. Cardiol. 59, 751-63 (2012
52. Seif-Naraghi S. B., et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci. Transl. Med. 5, 173ra25 (2013
53. Lin Y.-D., et al. Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs. Circulation 122, S132-41 (2010
54. Mazo M., et al. Treatment of reperfused ischemia with adipose-derived stem cells in a preclinical Swine model of myocardial infarction. Cell Transplant. 21, 2723-33 (2012
55. Gavira J. J., et al. Repeated implantation of skeletal myoblast in a swine model of chronic myocardial infarction. Eur. Heart J. 31, 1013-21 (2010
56. Meller J., Herman M. V., & Teichholz L. E. Noninvasive assessment of left ventricular function. Adv. Intern. Med. 24, 331-57 (1979
57. Kerut E. K., et al. Technique and imaging for transthoracic echocardiography of the laboratory pig. Echocardiography 21, 439-42 (2004
58. Weidemann F., et al. Myocardial function defined by strain rate and strain during alterations in inotropic states and heart rate. Am. J. Physiol. Heart Circ. Physiol. 283, H792-9 (2002
59. Minguell J. J., Lorino R., & Lasala G. P. Myocardial implantation of a combination stem cell product by using a transendocardial MYOSTAR injection catheter: A technical assessment. Acute Card. Care 13, 40-2 (2011
60. Krause K., et al. Percutaneous intramyocardial stem cell injection in patients with acute myocardial infarction: first-in-man study. Heart 95, 1145-52 (2009